Author's posts
More Covid-19 Testing Is The Answer. But How?
To boost Covid-19 testing capacity, we need to understand the key roadblocks.
A Biotech VC’s Prescription For What Ails Pharma
How can we balance innovation and affordability in prescription drugs? Peter Kolchinsky has some ideas.
How Smart Pharma Can Stop Making Bad R&D Choices
Drug companies need to ditch R&D group-think and embrace tough love from outside experts.
When Biotechs Get Breakthrough Therapy Status, Mr. Market Yawns
Biotechs crow about getting special treatment at FDA — but our data show investors don’t give them much credit.
The Cost-Benefit Revolution Is Far From Over
In his new book, Cass Sunstein explores how to bring analytic rigor to policy decisions.
